Based on this, monoclonal antibodies such as Secukinumab and Ixekizumab (anti-IL-17A), or those targeting the IL-17 receptor, including Brodalumab, could be considered as potential therapies for MG. The gene discussed is IL17A; the disease is myasthenia gravis.